Open AccessChemotherapy effectively suppresses interleukin-20, receptor activator of nuclear factor kappa-B ligand, and osteoprotegerin levels in patients with lung adenocarcinoma and bone metastasis
Author(s) -
Mingyang Yu,
Yishi Su,
Daping Cui,
Qiang Sun,
Bowu Luan,
Dewei Zhao
Publication year - 2016
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.179085
Subject(s) - osteoprotegerin , rankl , medicine , lung cancer , osteoclast , chemotherapy , adenocarcinoma , bone metastasis , cytokine , rank ligand , metastasis , receptor , oncology , endocrinology , activator (genetics) , cancer research , cancer
Bone metastasis (BM) is common in patients with lung cancer. Osteolysis is caused by increased osteoclast activity. Interleukin-20 (IL-20) and receptor activator of nuclear factor kappa-B ligand (RANKL) are crucial for osteoclast formation. Osteoprotegerin (OPG) inhibits a receptor activator of RANKL/RANK signaling. The aims of this study were to analyze the serum levels of IL-20, OPG, and RANKL in patients with and without BM and to observe the effect of chemotherapy on these cytokines.